Syapse experts Anna Berry, Mary Tran, and Michael Italia share how to establish high quality, real-world datasets by using a multi-source strategy.
A single source of data is often not enough to generate meaningful real-world evidence. Have you recently made an investment in a large raw real-world dataset, and are now drowning in data but lacking in evidence?
Watch as experts highlight strategic approaches you and your organization should consider as you invest in RWD to best capture the comprehensive patient journey needed to answer your most challenging questions, or seek to validate real-world endpoints.
Key Topics Include:
- Awareness on various RWD sources and their attributes, and how they are used to fill in the gaps to ensure your study design best reflects what is happening in the real-world
- Understanding whether artificial intelligence (AI) is a magical cure-all, or is it perpetuating inconsistencies or biases already in the data?
- How to take unstructured lab and pathology reports (including biomarker data) using NLP to ensure your study design best reflects what is happening in the real-world to generate more robust data
Presenters
Vice President
Molecular Pathology, Genomics and Laboratory Medicine
Syapse
Dr. Anna Berry is a thought leader in molecular oncology and personalized medicine, and experienced Scientific and Medical Director with a demonstrated history of working in the hospital & health care industry. Skilled in Oncology, Molecular Oncology, Molecular Biology, Healthcare Information Technology (HIT), and Healthcare Management.
SVP and GM, Data Insights
Data Insights
www.Syapse.com
Vice President
Product Development
Syapse
Michael Italia is focused on oncology precision medicine and real world evidence as VP of Product Development for Syapse. He leads teams to design and build complex, data-centric software applications in life science and healthcare.
Production Partner
Syapse
Advancing care requires real insights and collaboration. At Syapse, we start by analyzing real-world data to generate deep, quality insights that improve outcomes for all people with cancer.
Related Content
Improving Patient Outcomes: AI-Based Phenotyping for Diagnosis, Treatment, and Clinical Trials
Join a panel of OM1’s clinical experts in cardiometabolic disease, immunology, and mental health as they explore how Artificial Intelligence (AI) can find phenotypic patterns and unlock insights hidden in real-world data.
Bridging the Gap: Strategies for Patient-Centered Real-World Evidence in Rare Diseases
Watch this webinar exploring real challenges and solutions for generating patient-centered real-world evidence (RWE) in the context of rare diseases to support clinical development through commercial post-approval.
The role of patient-centric technologies & tokenization in RWE studies
Join the Castor team on the 3rd May 2023 with Aaron Berger from UBC & Ryan Moog from Datavant where we will dive deep into all things RWE, patient-centric technologies and the role of tokenization in clinical trials. You will hear about RWE case studies from the experts, learn new trends in the adoption of DCTs and how the role of patient-centric technologies & tokenization can contribute to successful RWE studies.